Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2023 | 1128 | 1.570 |
Why?
|
| Carcinoma, Lobular | 4 | 2023 | 23 | 1.310 |
Why?
|
| Kidney | 5 | 2013 | 394 | 1.210 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2023 | 47 | 0.880 |
Why?
|
| Breast Diseases | 4 | 2011 | 39 | 0.500 |
Why?
|
| Immunohistochemistry | 7 | 2013 | 848 | 0.470 |
Why?
|
| Breast | 3 | 2006 | 173 | 0.470 |
Why?
|
| Carcinoma in Situ | 2 | 2005 | 33 | 0.460 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 137 | 0.440 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2013 | 6 | 0.430 |
Why?
|
| Mammary Glands, Human | 3 | 2019 | 50 | 0.400 |
Why?
|
| Biopsy | 4 | 2011 | 375 | 0.360 |
Why?
|
| Calcinosis | 2 | 2020 | 79 | 0.360 |
Why?
|
| Fabry Disease | 1 | 2010 | 8 | 0.360 |
Why?
|
| Pulmonary Heart Disease | 1 | 2010 | 2 | 0.360 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 630 | 0.330 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 34 | 0.320 |
Why?
|
| Osteopontin | 1 | 2009 | 22 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 193 | 0.310 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2008 | 9 | 0.310 |
Why?
|
| Lymphoma, B-Cell | 2 | 2005 | 59 | 0.300 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 171 | 0.300 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 8 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 32 | 0.250 |
Why?
|
| Artifacts | 1 | 2006 | 126 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2019 | 155 | 0.240 |
Why?
|
| Humans | 31 | 2023 | 59810 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 65 | 0.240 |
Why?
|
| Lymph Nodes | 2 | 2023 | 212 | 0.240 |
Why?
|
| Female | 21 | 2023 | 31095 | 0.240 |
Why?
|
| Axilla | 1 | 2023 | 16 | 0.210 |
Why?
|
| Touch | 1 | 2023 | 28 | 0.210 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 36 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 40 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 71 | 0.200 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 16 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 21 | 0.200 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 15 | 0.200 |
Why?
|
| Pathology | 1 | 2002 | 11 | 0.200 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.200 |
Why?
|
| Epithelial Cells | 4 | 2022 | 376 | 0.190 |
Why?
|
| HIV Infections | 1 | 2008 | 927 | 0.190 |
Why?
|
| Nucleic Acid Conformation | 1 | 2002 | 231 | 0.180 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 20 | 0.180 |
Why?
|
| Osteolysis | 2 | 2011 | 17 | 0.180 |
Why?
|
| Polymers | 3 | 2016 | 317 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 2019 | 843 | 0.180 |
Why?
|
| Adenoma | 1 | 2020 | 64 | 0.180 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 461 | 0.170 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 124 | 0.160 |
Why?
|
| Estrogens | 1 | 2020 | 113 | 0.160 |
Why?
|
| Alkanes | 2 | 2009 | 15 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2010 | 137 | 0.160 |
Why?
|
| CpG Islands | 1 | 2020 | 212 | 0.160 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2009 | 220 | 0.150 |
Why?
|
| Transcriptome | 2 | 2019 | 334 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2020 | 273 | 0.150 |
Why?
|
| Adult | 11 | 2020 | 15882 | 0.150 |
Why?
|
| Middle Aged | 11 | 2020 | 16400 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 483 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6041 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 351 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 83 | 0.140 |
Why?
|
| Phosphorylcholine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2016 | 99 | 0.130 |
Why?
|
| Prodrugs | 1 | 2016 | 32 | 0.130 |
Why?
|
| Rhodiola | 1 | 2015 | 15 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 42 | 0.120 |
Why?
|
| Mammography | 3 | 2020 | 273 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2017 | 349 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 584 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 707 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 128 | 0.110 |
Why?
|
| Radiography | 2 | 2005 | 513 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 162 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 647 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 30 | 0.100 |
Why?
|
| Parity | 1 | 2013 | 71 | 0.100 |
Why?
|
| Morphogenesis | 2 | 2012 | 113 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1538 | 0.100 |
Why?
|
| Toll-Like Receptor 1 | 2 | 2009 | 22 | 0.100 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 14 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2012 | 79 | 0.100 |
Why?
|
| Joint Prosthesis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2013 | 249 | 0.100 |
Why?
|
| Foreign-Body Reaction | 1 | 2011 | 15 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2011 | 28 | 0.090 |
Why?
|
| Vasculitis | 1 | 2011 | 51 | 0.090 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 71 | 0.090 |
Why?
|
| Young Adult | 4 | 2020 | 4363 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 68 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 82 | 0.090 |
Why?
|
| Stem Cells | 1 | 2013 | 257 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 906 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 160 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 131 | 0.080 |
Why?
|
| Asepsis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dyspnea | 1 | 2010 | 108 | 0.080 |
Why?
|
| Dendritic Cells | 3 | 2009 | 508 | 0.080 |
Why?
|
| Mastocytosis, Systemic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Nephrons | 1 | 2009 | 7 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2010 | 259 | 0.080 |
Why?
|
| Kidney Tubules | 1 | 2009 | 18 | 0.080 |
Why?
|
| Lysosomes | 2 | 2009 | 163 | 0.080 |
Why?
|
| Ureter | 1 | 2009 | 20 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2005 | 2341 | 0.080 |
Why?
|
| Aged | 6 | 2020 | 13461 | 0.080 |
Why?
|
| Epithelium | 1 | 2009 | 97 | 0.080 |
Why?
|
| Organogenesis | 1 | 2009 | 40 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2008 | 48 | 0.080 |
Why?
|
| Endosomes | 1 | 2009 | 169 | 0.080 |
Why?
|
| Gestational Age | 1 | 2009 | 184 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 267 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 153 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 454 | 0.070 |
Why?
|
| Cysts | 1 | 2007 | 37 | 0.070 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 2006 | 3 | 0.070 |
Why?
|
| Vacuum | 1 | 2006 | 8 | 0.070 |
Why?
|
| Scrotum | 1 | 2006 | 4 | 0.070 |
Why?
|
| Genital Diseases, Male | 1 | 2006 | 9 | 0.070 |
Why?
|
| Epididymis | 1 | 2006 | 27 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1460 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2005 | 185 | 0.060 |
Why?
|
| Myeloid Cells | 1 | 2005 | 92 | 0.060 |
Why?
|
| Reoperation | 1 | 2005 | 257 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2005 | 179 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 942 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 492 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1106 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 1975 | 0.050 |
Why?
|
| Pseudolymphoma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Electrophoresis, Capillary | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Microtomy | 1 | 2002 | 3 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 51 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 38 | 0.050 |
Why?
|
| Mice | 4 | 2019 | 10305 | 0.050 |
Why?
|
| Clone Cells | 1 | 2002 | 106 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 244 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 183 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2002 | 54 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 1379 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2002 | 291 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1996 | 0.050 |
Why?
|
| Phenotype | 2 | 2017 | 1154 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1559 | 0.050 |
Why?
|
| Nipples | 1 | 2020 | 14 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 498 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 397 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 5 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1297 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 47 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 1205 | 0.040 |
Why?
|
| Base Sequence | 1 | 2002 | 1311 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 85 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 5149 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 807 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 118 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 302 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2005 | 3110 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 139 | 0.040 |
Why?
|
| Adolescent | 3 | 2020 | 5939 | 0.040 |
Why?
|
| Comorbidity | 2 | 2011 | 1091 | 0.040 |
Why?
|
| Animals | 4 | 2019 | 19717 | 0.040 |
Why?
|
| Male | 4 | 2011 | 27766 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 661 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 50 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 305 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 42 | 0.030 |
Why?
|
| Monocytes | 2 | 2009 | 344 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1584 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 2359 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2100 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 506 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 511 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1040 | 0.030 |
Why?
|
| Axin Protein | 1 | 2012 | 10 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 26 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2012 | 91 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2079 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 99 | 0.020 |
Why?
|
| Prednisone | 1 | 2011 | 80 | 0.020 |
Why?
|
| Gynecomastia | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 102 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 206 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2011 | 172 | 0.020 |
Why?
|
| Polyethylenes | 1 | 2009 | 6 | 0.020 |
Why?
|
| Giant Cells | 1 | 2009 | 17 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2009 | 23 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3590 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2011 | 256 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 434 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2890 | 0.020 |
Why?
|
| Collagen | 1 | 2009 | 119 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 176 | 0.020 |
Why?
|
| Mast Cells | 1 | 2009 | 41 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 131 | 0.020 |
Why?
|
| Mammaplasty | 1 | 2009 | 44 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2008 | 50 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 82 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 253 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 402 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 449 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 710 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 638 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 63 | 0.020 |
Why?
|
| trans-Golgi Network | 1 | 2005 | 7 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2005 | 27 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 55 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 72 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2005 | 141 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 167 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 459 | 0.010 |
Why?
|
| Macrophages | 1 | 2009 | 1008 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 2002 | 15 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2002 | 19 | 0.010 |
Why?
|
| Keratins | 1 | 2002 | 31 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2005 | 771 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1579 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 545 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1527 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5038 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 5205 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 343 | 0.010 |
Why?
|